Chemiluminescent immunoassay for detection of HIV antigen and antibody: technical advantages and clinical application progress

Technical Principles and Detection Targets

The Human Immunodeficiency Virus Antigen and Antibody Detection Kit (Chemiluminescence Immunoassay) employs the double-antigen sandwich or double-antibody sandwich principle to simultaneously detect HIV-1 and HIV-2 antibodies as well as p24 antigen. The kit is coated with recombinant HIV antigens and anti-p24 antibodies. When corresponding antibodies or antigens are present in the sample, immune complexes are formed, which subsequently bind to enzyme-labeled antibodies or antigens, generating photon signals through a chemiluminescent substrate. The instrument reads the photon counts and compares them with a standard curve to obtain qualitative or quantitative results. This technology advances antigen detection to approximately 2-3 weeks after infection. Compared with third-generation reagents that detect antibodies only, the window period can be shortened by approximately 1 week, facilitating early detection of acute-phase infected individuals.

Clinical Significance of Window Period Shortening

After HIV infection, there exists a serological "window period" during which antibodies have not yet been produced, but p24 antigen can be detected 14-21 days post-infection. The Human Immunodeficiency Virus Antigen and Antibody Detection Kit (Chemiluminescence Immunoassay) significantly reduces the risk of missed detection during the window period through combined antigen and antibody detection. It is of significant value for early diagnosis following exposure in high-risk populations, blood transfusion safety screening, and identification of acute-phase cases. It should be noted that any detection method has a window period and cannot completely rule out very early-stage infection. Confirmation with nucleic acid testing or regular follow-up is recommended.

Advantages of Automation and High-Throughput Operation

The chemiluminescence immunoassay platform supports fully automated processing, including sample loading, incubation, washing, luminescent signal reading, and result interpretation. Dozens to hundreds of specimens can be tested in a single batch, with a typical assay turnaround time of 30-60 minutes. For routine screening in tertiary hospitals or blood banks, this effectively improves testing efficiency and reduces manual operation errors. The kit has good stability, generally stored at 2-8°C for 12-18 months. Post-opening stability should be referenced to the specific instructions for use.

Clinical Application Scenarios and Precautions

This kit is primarily suitable for HIV screening in medical institutions, blood banks, and centers for disease control and prevention. According to the National Technical Guidelines for HIV Testing, initially reactive specimens must be retested using reagents based on different principles (such as enzyme-linked immunosorbent assay or another brand of chemiluminescent reagent). Retested reactive specimens should be sent to a confirmation laboratory for Western blot or nucleic acid testing. During use, strictly follow the instructions for operation, avoid interference from hemolyzed or lipemic samples, and conduct regular internal quality control and performance verification. If the luminescence value is near the cutoff value, resampling for testing or confirmation using an alternative method is recommended.